King Felipe VI, Salvador Illa, and La Caixa Foundation President Launch Spain’s First Specialized Immunology Research Center

King Felipe VI, Salvador Illa and Isidro Fainé inaugurated Spain’s first dedicated immunology research centre in Barcelona on Thursday, marking a significant step in the nation’s biomedical strategy. The facility, located within the Parc Científic de Barcelona, brings together public and private investment to advance research into autoimmune diseases, cancer immunotherapy and infectious disease responses. King Felipe VI attended in his capacity as honorary president of the Spanish National Research Council (CSIC), while Salvador Illa, President of the Generalitat de Catalunya, and Isidro Fainé, President of Fundación La Caixa, represented the regional and philanthropic partners driving the initiative. Fundación La Caixa has committed €40 million over ten years to support the centre’s operations, including recruitment of international scientists and development of clinical trial infrastructure. The Generalitat contributed €15 million for building adaptation and equipment, with additional funding from the Spanish Ministry of Science and Innovation through the PERTE for Vanguard Health programme. The centre will operate under a public-private consortium model, led by the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) in partnership with the Hospital Clínic de Barcelona and the Universitat de Barcelona. Its initial research agenda focuses on translating basic immunology findings into therapies for lupus, rheumatoid arthritis and solid tumours, with plans to launch Phase I trials by 2027. Officials emphasized the centre’s role in reducing reliance on foreign biotech imports and strengthening Spain’s position in the European Research Area. No timeline was provided for full operational capacity, though staffing is expected to reach 120 researchers and technicians by the conclude of 2026. The inauguration concluded without public questions or further announcements regarding future expansion or international collaboration agreements.